Correlation between Ultrasonographic Appearance of Papillary Thyroid Microcarcinoma and BRAF V600E Mutation

Liang, Songnian; Huang, Kun

doi:10.1155/2022/5916379

Cited by 5 publications

(5 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Surprisingly, the positive BRAF V600E mutation was increased in older patients in benign cytology and in the nodules classi ed both TI-RADS 4a and TBSRTC II. Several US features, such as the presence of microcalci cations, marked hypoechogenicity, irregular margins have been reported to predict malignancy [37,38], and were associated with BRAF V600E mutation in thyroid nodules [39]. However, in our study, the US features mentioned above had no signi cant difference between positive and negative BRAF V600E mutation.…”

Section: Discussioncontrasting

confidence: 68%

Age and BRAFV600E Mutation Stratified Patients with Cytologically Benign Thyroid Nodules

Huang¹,

Liu²,

Liang³

et al. 2023

Preprint

View full text Add to dashboard Cite

Background BRAF V600E mutation has high specificity in diagnosing papillary thyroid cancer (PTC) in benign cytological thyroid nodules. However, to avoid overdiagnosis and overtreatment, the BRAFV600E mutation detection was un-practical and not required immediately in benign cytology. A definitive diagnosis to distinguish positive BRAFV600E mutation in benign cytological results is desperately needed. Our objective was to identify the clinical characteristics associated with positive BRAFV600E mutation in cytologically benign thyroid nodules, which would allow to screen patients who may benefit from BRAFV600E mutation testing and further surgical intervention.Methods We analysis the clinical characteristics correlated with BRAFV600E mutation in our detection cohort, including 204 patients with 217 thyroid nodules, and separate analyses were performed in benign cytology and in patients with thyroid imaging reporting and data system (TI-RADS) classification 4a. Differential expression genes between positive and negative BRAFV600E mutation groups and older and younger age groups were assessed in Asian patients with thyroid cancer from the Cancer Genome Atlas (TCGA) dataset, and the association of age and BRAFV600E mutation with immune response were also evaluated.Results BRAF V600E mutations is a risk factor in screening malignancy in benign cytological classification, furthermore, the positive BRAFV600E mutation frequency was higher in patients older than 50 years (p = 0.0012) of cytologically benign thyroid nodules. Similarly, the positive BRAFV600E mutation was associated with patients age in TI-RADS classification 4a (p < 0.001), which ultrasound features could not provided predictive information for BRAFV600E mutation detection. BRAFV600E mutations as a risk factor for malignancy, had upregulated in advanced pathological T stage (p < 0.001) and N stage (p < 0.001) in TCGA-THCA cohort. And in thyroid nodules, BRAFV600E mutation was significantly associated with Ultrasound classification (p < 0.001) and fine needle aspiration (FNA) category (p < 0.001).Conclusions BRAF V600E mutation is an accurate adjunctive diagnostic marker on FNA to screen malignancy. In benign cytology, patients older than 50 years are more likely to have positive BRAFV600E mutation, which may associate with immune response and have higher risk of malignancy. Thus, the BRAFV600E mutation detection and further surgery should be strengthened in older patients with benign cytologically thyroid nodules.

show abstract

Section: Discussioncontrasting

confidence: 68%

Age and BRAFV600E Mutation Stratified Patients with Cytologically Benign Thyroid Nodules

Huang¹,

Liu²,

Liang³

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…17 Several US features, such as microcalcification, marked hypoechogenicity and irregular margins were more frequently observed in thyroid nodules harbouring positive BRAF V600E mutation than negative BRAF V600E mutation. 30,39 In our study, there were no significant differences in C-TIRADS classification, along with US features between positive and negative BRAF V600E mutation in benign cytologic results. The reason may be that the majority of cases were classified as 3-4a, so the result of C-TIRADS classification was not referential.…”

Section: Discussionmentioning

confidence: 45%

Age and BRAFV600E Mutation Stratified Patients with Cytologically Benign Thyroid Nodules

Huang,

Liu,

Han

et al. 2023

IJGM

View full text Add to dashboard Cite

Our objective was to evaluate the diagnostic performance of BRAF V600E mutation for malignant, and to identify clinical characteristics associated with positive BRAF V600E mutation in low-risk cytological and ultrasound diagnostic thyroid nodules. This aims to identify patients who may benefit from BRAF V600E mutation testing and subsequent surgical intervention. Patients and Methods: We analysis the clinical characteristics correlated with BRAF V600E mutation in our detection cohort, including 204 patients with 217 thyroid nodules, and separate analyses were performed in 103 thyroid nodules with benign cytological result. Signaling pathway and immune response associated with age and BRAF V600E mutation status were also evaluated in Asian patients with thyroid cancer from the Cancer Genome Atlas (TCGA) dataset. Results:The positive BRAF V600E mutation was significantly associated with higher Ultrasound (US) classification (p<0.001) and fineneedle aspiration (FNA) categories (p<0.001). BRAF V600E mutation as a risk factor for malignancy, showing the optimal diagnostic efficacy for malignancy combined with FNA categories, with the AUC was 0.923. Otherwise, BRAF V600E mutation is a risk factor in screening malignancy in low-risk FNA and US classification, which is significant correlation with patients age. Patients over 50 years old exhibiting a higher percentage of positive BRAF V600E mutation when both ultrasound and FNA results indicate benign conditions, with higher risk of malignancy. Conclusion: BRAF V600E mutation is an accurate adjunctive diagnostic marker on FNA to screen malignancy. In low risk of both ultrasound and FNA results, the positive BRAF V600E was significant increased in patients over 50 years old, which have higher risk of malignancy. Thus, the BRAF V600E mutation detection and further surgery should be strengthened in older patients with benign cytological and US results thyroid nodules.

show abstract

“… 32 Experimental findings indicate that BRAF V600E-mutated thyroid cancers display higher regional cervical lymph node metastases rates than non-mutated ones, suggesting a strong correlation with thyroid carcinogenesis, extraperitoneal cancer spread, recurrence, and lymph node metastases, echoing prior research. 33 , 34 This information aids surgeons in determining appropriate surgical strategies during initial procedures. 35 , 36 Nucera et al’s experiments demonstrated that PLX4720, a specific BRAF V600E inhibitor, suppresses BRAF V600E thyroid cancer cell migration and invasion, thereby reducing tumor aggression.…”

Section: Discussionmentioning

confidence: 99%

Modified TI-RADS Coupled with BRAFV600E Enhances Diagnostic Efficiency in Papillary Thyroid Carcinoma: Prospective Study

Wang,

Cheng,

2024

IJGM

View full text Add to dashboard Cite

Correlation between Ultrasonographic Appearance of Papillary Thyroid Microcarcinoma and BRAF V600E Mutation

Cited by 5 publications

References 38 publications

Age and BRAFV600E Mutation Stratified Patients with Cytologically Benign Thyroid Nodules

Age and BRAFV600E Mutation Stratified Patients with Cytologically Benign Thyroid Nodules

Age and BRAFV600E Mutation Stratified Patients with Cytologically Benign Thyroid Nodules

Modified TI-RADS Coupled with BRAFV600E Enhances Diagnostic Efficiency in Papillary Thyroid Carcinoma: Prospective Study

Contact Info

Product

Resources

About